Eric Sachetta Buys 37,537 Shares of Sensus Healthcare (NASDAQ:SRTS) Stock

Posted by Stanley Muller on Sep 2nd, 2026

Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) Director Eric Sachetta bought 37,537 shares of Sensus Healthcare stock in a transaction on Friday, August 28th. The shares were bought at an average cost of $3.44 per share, with a total value of $129,127.28. Following the acquisition, the director directly owned 267,480 shares in the company, valued at approximately $920,131.20. This represents a 16.32% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Eric Sachetta also recently made the following trade(s):

On Monday, August 31st, Eric Sachetta purchased 27,304 shares of Sensus Healthcare stock. The shares were bought at an average price of $3.54 per share, for a total transaction of $96,656.16.
On Thursday, August 27th, Eric Sachetta purchased 10,925 shares of Sensus Healthcare stock. The stock was purchased at an average cost of $3.18 per share, for a total transaction of $34,741.50.
On Wednesday, August 26th, Eric Sachetta acquired 9,708 shares of Sensus Healthcare stock. The stock was purchased at an average price of $3.29 per share, with a total value of $31,939.32.
On Monday, August 24th, Eric Sachetta acquired 34,697 shares of Sensus Healthcare stock. The stock was purchased at an average price of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Trading Down 5.9%

Shares of NASDAQ:SRTS opened at $3.33 on Wednesday. The company has a 50 day moving average of $3.08 and a 200 day moving average of $3.50. The stock has a market cap of $54.82 million, a P/E ratio of -3.54 and a beta of 1.10. Sensus Healthcare, Inc. has a 12 month low of $2.66 and a 12 month high of $5.49.

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $4.60 million.

Analyst Ratings Changes

Several research firms recently issued reports on SRTS. Wall Street Zen lowered Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Weiss Ratings downgraded Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Finally, Lake Street Capital cut their price objective on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a report on Friday, August 14th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.83.

Read Our Latest Stock Analysis on SRTS

Institutional Trading of Sensus Healthcare

A number of hedge funds have recently made changes to their positions in the stock. EP Wealth Advisors LLC bought a new position in Sensus Healthcare in the second quarter valued at $49,000. XTX Topco Ltd bought a new stake in Sensus Healthcare during the fourth quarter worth about $77,000. Jane Street Group LLC bought a new stake in Sensus Healthcare during the fourth quarter worth about $79,000. Ingalls & Snyder LLC purchased a new position in shares of Sensus Healthcare in the 4th quarter worth about $219,000. Finally, BlackRock Inc. purchased a new position in shares of Sensus Healthcare in the 2nd quarter worth about $252,000. 25.30% of the stock is owned by institutional investors.

Sensus Healthcare Company Profile

(Get Free Report)

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.